Download PDF
Z Gastroenterol 2014; 52(10): 1185-1197
DOI: 10.1055/s-0033-1362816
Leitlinie
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C

Addendum zur Hepatitis C Leitlinie im Auftrag der folgenden Fachgesellschaften:
DGVS, bng, Kompetenznetz Hepatitis / Deutsche Leberstiftung, DGP, Berufsverband Deutscher Pathologen, GfV, GPGE, SGG, ÖGGH, DTG, Deutsche Leberhilfe e. V.
Christoph Sarrazin
1   Universitätsklinikum Frankfurt am Main, Med. Klinik 1, Frankfurt am Main
,
Thomas Berg
2   Sektion Hepatologie; Klinik für Gastroenterologie und Rheumatologie, Universitätsklinikum Leipzig
,
Peter Buggisch
3   Leberzentrum Hamburg im IFI an der Askleopios Klinik St. Georg, Hamburg
,
Matthias Dollinger
4   Universitätsklinikum Ulm
,
Holger Hinrichsen
5   Gastroenterologisch-Hepatologisches Zentrum Kiel
,
Dietrich Hüppe
6   Gastroenterologische Gemeinschaftspraxis Herne
,
Michael Manns
7   Medizinische Hochschule Hannover
,
Stefan Mauss
8   Zentrum für HIV und Hepatogastroenterologie, Düsseldorf
,
Jörg Petersen
3   Leberzentrum Hamburg im IFI an der Askleopios Klinik St. Georg, Hamburg
,
Karl-Georg Simon
9   MVZ für Gastroenterologie und Hepatologie, Leverkusen
,
Ingo van Thiel
10   Deutsche Leberhilfe e. V., Köln
,
Heiner Wedemeyer
7   Medizinische Hochschule Hannover
,
Stefan Zeuzem
1   Universitätsklinikum Frankfurt am Main, Med. Klinik 1, Frankfurt am Main
› Author Affiliations
Further Information

Publication History

Publication Date:
20 October 2014 (online)

Also available at
    Permissions and Reprints

Präambel

Mit der Zulassung neuer direkt antiviral wirksamer Medikamente kommt es zu einer wichtigen Erweiterung des Spektrums der Behandlung der chronischen Hepatitis-C-Virus-(HCV)-Infektion. Neben einer Verbesserung der dauerhaften virologischen Ansprechraten bei gleichzeitig verkürzter Therapiedauer für konventionelle PEG-Interferon / Ribavirin basierte Triple-Therapien stehen auch hocheffektive, kurze und nebenwirkungsarme Interferon-freie Therapiemöglichkeiten für bestimmte Patientengruppen zur Verfügung.

Vor diesem Hintergrund kann eine Triple-Therapie aus PEG-Interferon, Ribavirin und den Proteaseinhibitoren Boceprevir bzw. Telaprevir nicht mehr als Standardtherapie empfohlen werden.

Die folgenden Empfehlungen gelten für erwachsene Patienten mit chronischer Hepatitis C, sind bis zur Zulassung weiterer Therapiemöglichkeiten gültig und werden im Verlauf mit der Verfügbarkeit neuer Substanzen zeitnah aktualisiert.

 

  • Referenzen

  • 1 Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887
    CrossrefPubMedGoogle Scholar
  • 2 Kowdley KV, Lawitz E, Crespo I et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-2107
    CrossrefPubMedGoogle Scholar
  • 3 Pol S, Sulkowski M, Hassanein T et al. Successful retreatment with sofosbuvir of HCV genotype-1 infected patients who failed prior therapy with peginterferon and ribavirin plus 1 or 2 additional direct-acting antiviral agents. Journal of Hepatology 2014; 60: S23-S23
    PubMedGoogle Scholar
  • 4 Lawitz E, Poordad F, Brainard D et al. Sofosbuvir in combination with PEG-IFN and ribavirin for 12 weeks provides high SVR rates in HCV infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the Lonestar-2 study. Hepatology 2013; 58: LB-4
    PubMedGoogle Scholar
  • 5 Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221
    CrossrefPubMedGoogle Scholar
  • 6 Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493
    CrossrefPubMedGoogle Scholar
  • 7 Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44
    CrossrefPubMedGoogle Scholar
  • 8 Osinusi A, Meissner EG, Lee YJ et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-811
    CrossrefPubMedGoogle Scholar
  • 9 Lalezari JP, Nelson DR, Hyland RH et al. Once Daily Sofosbuvir Plus Ribavirin for 12 and 24 Weeks in Treatment-Naive Patients with Hcv Infection: the Quantum Study. Journal of Hepatology 2013; 58: S346-S346
    PubMedGoogle Scholar
  • 10 Forns X, Lawitz E, Zeuzem S et al. Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial. Gastroenterology 2014;
    PubMedGoogle Scholar
  • 11 Manns M, Marcellin P, Poordad F et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;
    PubMedGoogle Scholar
  • 12 Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;
    PubMedGoogle Scholar
  • 13 Vermehren J, Aghemo A, Falconer K et al. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J Hepatol 2014; 60: 913-919
    CrossrefPubMedGoogle Scholar
  • 14 Reddy K, Zeuzem S, Zoulim F et al. A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study. Hepatol Int 2014; 8: S397
    PubMedGoogle Scholar
  • 15 Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;
    PubMedGoogle Scholar
  • 16 Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898
    CrossrefPubMedGoogle Scholar
  • 17 Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888
    CrossrefPubMedGoogle Scholar
  • 18 Hezode C, Hirschfield GM, Ghesquiere W et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2014;
    PubMedGoogle Scholar
  • 19 Zeuzem S, Hezode C, Bronowicki JP et al. Daclatasvir in combination with simeprevir with or without ribavirin for hepatitis C virus genotype 1 infection. 21st Conferences on Retroviruses and Opportunistic Infections; 2014
    PubMedGoogle Scholar
  • 20 Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011; 364: 2405-2416
    CrossrefPubMedGoogle Scholar
  • 21 Bacon BR, et al. Poordad F, McCone Jr J. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206
    CrossrefPubMedGoogle Scholar
  • 22 Sarrazin C, Schwendy S, Müller B et al. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24–72 weeks. Gastroenterology 2011; 141: 1656-1664
    CrossrefPubMedGoogle Scholar
  • 23 Sarrazin C, Berg T, Ross RS et al. Update der S3-Leitlinie Prophylaxe, Diagnose und Therapie der Hepatitis C Virus (HCV) Infektion. Z Gastroenterol 2010; 48: 289-351
    Google Scholar
  • 24 Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877
    CrossrefPubMedGoogle Scholar
  • 25 Lawitz E, Lalezari JP, Hassanein T et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-408
    CrossrefPubMedGoogle Scholar
  • 26 Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001
    CrossrefPubMedGoogle Scholar
  • 27 Ruane PJ, Ain D, Meshrekey R et al. Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naive and treatment-experienced patients with chronic genotype 4 HCV infection. Journal of Hepatology 2014; 60: S503-S504
    PubMedGoogle Scholar
  • 28 Moreno C, Hezode C, Marcellin P et al. Once-daily simeprevir (TMC435) with peginterferon / ribavirin in treatment-naive or treatment-experienced chronic HCV genotype 4-infected patients: final results of a phase III trial. Journal of Hepatology 2014; 60: S535-S535
    PubMedGoogle Scholar
  • 29 Lenz O, Vijgen L, Berke JM et al. Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 2013; 58: 445-451
    CrossrefPubMedGoogle Scholar
  • 30 Sulkowski MS, Rodriguez-Torres M, Lalezari J et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (Photon-1). Hepatology 2013; 58: 313A
    CrossrefPubMedGoogle Scholar
  • 31 Rodriguez-Torres M, Rodriguez-Orengo J, Gaggar A et al. Sofosbuvir and peginterferon alfa-2a / ribavirin for treatment-naive genotype 1–4 HCV-infected patients who are coinfected with HIV. Infectious. Disease Week 2014 2014; Abstract 2014.
    PubMedGoogle Scholar
  • 32 Curry MP, Forns X, Chung R et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013; 58: 314A
    PubMedGoogle Scholar
  • 33 Lawitz E, Ghalib R, Rodriguez-Torres M et al. Simeprevir plus sofosbuvir with / without ribavirin in HCV genotype 1 prior null-responder / treatment-naive patients (Cosmos study): primary endpoint (SVR12) results in patients with metavir F3–4 (Cohort 2). Journal of Hepatology 2014; 60: S524-S524
    PubMedGoogle Scholar
  • 34 Sulkowski M, Jacobson IM, Ghalib R et al. Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with metavir F0–2: Cosmos study subgroup analysis. Journal of Hepatology 2014; 60: S4-S4
    PubMedGoogle Scholar
  • 35 Charlton M, Gane E, Manns MP et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infeciton after liver transplantation: preliminary results of a prospective, multicenter study. Hepatology 2013; 58: LB-2
    PubMedGoogle Scholar
  • 36 Pellicelli AM, Montalbano M, Lionetti R et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014;
    PubMedGoogle Scholar